Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.41
-3.4%
$1.42
$1.10
$2.81
$78.37M3.11142,784 shs39,491 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.70
+5.4%
$13.23
$0.80
$15.85
$22.00M1.272,297 shs830 shs
OncoCyte Co. stock logo
OCX
OncoCyte
$3.33
+2.5%
$2.99
$1.92
$4.75
$95.24M0.9558,050 shs37,955 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.35
+5.5%
$1.42
$1.10
$16.10
$82.87M1.431.10 million shs1.01 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-0.68%-5.19%-4.58%+4.29%-48.23%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
+5.38%+0.74%+8.73%-13.18%+661.11%
OncoCyte Co. stock logo
OCX
OncoCyte
-3.56%+10.54%-5.52%+26.46%+14.84%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-0.78%-6.57%-12.33%-58.97%-89.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectis S.A. stock logo
CLLS
Cellectis
3.0675 of 5 stars
3.55.00.00.01.82.50.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
2.7163 of 5 stars
3.44.00.00.03.50.80.6
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
4.3721 of 5 stars
4.03.00.04.72.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$6.67372.81% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
2.75
Moderate Buy$6.0682.06% Upside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31886.11% Upside

Current Analyst Ratings Breakdown

Latest FNCH, CLLS, PLRX, and OCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
OncoCyte Co. stock logo
OCX
OncoCyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/21/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $8.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/13/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
4/8/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
3/28/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/25/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.00
3/25/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
3/18/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/4/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.50
3/4/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$47.63M1.65N/AN/A$1.52 per share0.93
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$110K200.02N/AN/A$14.25 per share0.96
OncoCyte Co. stock logo
OCX
OncoCyte
$3.84M24.78N/AN/A$2.48 per share1.34
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M52.45N/AN/A$7.91 per share0.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
OncoCyte Co. stock logo
OCX
OncoCyte
-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%8/14/2025 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$161.34M-$3.61N/AN/AN/AN/A-48.91%-41.09%8/6/2025 (Estimated)

Latest FNCH, CLLS, PLRX, and OCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/12/2025Q1 2025
OncoCyte Co. stock logo
OCX
OncoCyte
-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million
3/24/2025Q4 2024
OncoCyte Co. stock logo
OCX
OncoCyte
-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million
3/13/2025Q4 2024
Cellectis S.A. stock logo
CLLS
Cellectis
$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million
3/3/2025Q4 2024
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.99-$0.82+$0.17-$0.82$0.08 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
0.48
1.78
1.78
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
OncoCyte Co. stock logo
OCX
OncoCyte
N/A
0.53
0.50
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
0.09
10.26
10.26

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
OncoCyte Co. stock logo
OCX
OncoCyte
55.35%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
OncoCyte Co. stock logo
OCX
OncoCyte
2.05%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
OncoCyte Co. stock logo
OCX
OncoCyte
12028.60 million17.18 millionNo Data
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.96 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.41 -0.05 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 +0.03 (+1.77%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.70 +0.70 (+5.38%)
As of 05/27/2025 03:20 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

OncoCyte stock logo

OncoCyte NASDAQ:OCX

$3.33 +0.08 (+2.46%)
Closing price 03:59 PM Eastern
Extended Trading
$3.34 +0.00 (+0.15%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.35 +0.07 (+5.47%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.00 (+0.37%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.